CDK 4/6 Inhibitors in Treating Breast Cancer
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer...
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
ImPassion130 Trial Outcomes
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizum...
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
MONALEESA-7 Trial Outcomes in Premenopausal Breast Cancer
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides the outcomes of the MONALEESA-& trial in premenopausal breast ...
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
SOPHIA Trial Outcomes
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School provides an overview...
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
Efficacy and Safety of Combination Eribulin + Pembrolizumab
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School elaborates on the ef...
Author: obr
Added: 07/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 2, 2019 Category: Cancer & Oncology Source Type: podcasts
